It is made available under a CC-BY-ND 4.0 International license .

Cost-effectiveness of dementia insurance for cognitively-unimpaired *APOE-* ε 4 homozygotes – a simulation study

1 Kenichiro Sato^{1,2}, Saki Nakashima³, Yoshiki Niimi^{2,4}, Takeshi Iwatsubo^{1,2,*}

- ¹ Department of Neuropathology, Graduate School of Medicine, The University of Tokyo
- ² Unit for Early and Exploratory Clinical Development, The University of Tokyo Hospital
- ³ Department of Neurology, Graduate School of Medicine, The University of Tokyo
- ⁴ Department of Healthcare Economics and Health Policy, Graduate School of Medicine, The
- 6 University of Tokyo
- 7

8 * Correspondence: Dr. Takeshi Iwatsubo (iwatsubo@m.u-tokyo.ac.jp)

9 **Running Title**: Cost-effectiveness of dementia insurance

Keywords: dementia insurance, *APOE*, ε4-homozygote, cost-effectiveness, Alzheimer's disease.

12 Abstract

13 Dementia insurance, a private insurance product covering the first diagnosis of dementia of the 14 insured, may be economical for asymptomatic individuals who are aware of their own high genetic 15 risk of developing Alzheimer's disease (AD) in advance. This is a retrospective study conducted 16 based on National Alzheimer's Coordinating Center (NACC) data including cognitively unimpaired 17 individuals, aiming to simulate income and expenses of dementia insurance for the insured 18 perspectives. Loss ratio (= total benefits gained / total premium paid) was calculated by APOE- ϵ 4 19 subgroup as a measure of cost-effectiveness, applying the premium rates of actual dementia 20 insurance products being sold in Japan. As a result, for up to 18 years of longitudinal follow-up, the 21 estimated cost-effectiveness improved over the longer observation periods. In individuals in their 60s 22 or older at baseline, the cost-effectiveness was best in the APOE- ϵ 4 homozygotes, followed by

It is made available under a CC-BY-ND 4.0 International license .

heterozygotes, and ε4-negative individuals. The dementia insurance for ε4-homozygotes for
observation periods ≥ 10 years in this age group was approximately 3 to 4 times more economical
than for ε4-negative individuals. Although actively pursuing *APOE* testing for asymptomatic
individuals may not be currently recommended due to the concern of adverse selection in the
insurance and the absence of available disease-modifying therapy approved for the preclinical stage
of AD, our study may provide an important basis for further investigating the advantages and
limitations of dementia insurance for asymptomatic individuals with pathogenic or high-risk genes.

31 **1 Introduction**

32 Along with the growing population of elderly individuals, there is an increasing awareness among 33 people of the need to prepare for life after retirement, including expenses for long-term care services 34 and medical care services [Yamazaki 2020]. In line with this trend, a private insurance product called 35 "dementia insurance" has been introduced over the past 10-20 years in some countries such as South 36 Korea [Park 2017; RGA HP] and Japan [Šestáková 2019; Goncharova 2020; Eisai HP]. The 37 dementia insurance product is typically designed as diagnostic coverage for middle-aged or elderly 38 non-demented individuals, providing a predetermined insurance benefit if the insured individuals are 39 diagnosed with dementia at certain stages for the first time during the policy period [Eisai HP]. 40 Additional benefits are sometimes provided, such as coverage for dementia prevention, dementia 41 treatment, long-term care services, and medical care services [Park 2017; RGA HP]. 42 In Japan, a super-aging society [Muramatsu 2011] where elderly population comprised 29% 43 in 2021 [eStat], the sale of dementia insurance is reportedly not very popular (e.g., 6.6% of 44 households from a 2021 survey of 4,000 in Japan had purchased it [Japanese Institute of Life 45 Insurance]). This may be due, in part, to the good availability of national health and long-term care 46 (LTC) insurance [Tamiya 2011]. A typical dementia insurance product for older individuals (e.g., 47 aged 60 years) requires the insured to pay thousands of JPY as a monthly premium (c.f., USD 1 =48 JPY 160 in early July 2024) for life, with a benefit amount of JPY 1,000,000 (i.e., USD 6,250 when

It is made available under a CC-BY-ND 4.0 International license .

49 1 USD = JPY 160) upon the occurrence of an event (e.g., first diagnosis of dementia and/or

50 certification as requiring nursing care in the long-term care insurance system).

51 If a person knew that they had an objectively high risk of developing dementia in the future, 52 they might consider it beneficial for them to purchase a dementia insurance policy while still 53 cognitively unimpaired. However, such objective information is usually not available. For this reason, 54 dementia insurance might be viewed as a viable insurance product for private insurance companies 55 that need to make a profit.

56 Meanwhile, in some rare cases, people have been found to have an objectively high risk of 57 developing AD, which is the most common cause of dementia [Jack 2013]. These include those with 58 familial AD mutations or two APOE-e4 alleles [Liu 2013; Nicolas 2016; Husain 2021; Fortea 2023]. 59 APOE- ϵ 4 homozygotes are at very high risk of developing AD (e.g., odds ratio (OR) 5.9 in ϵ 4/ ϵ 3 and 60 OR 33.1 in $\varepsilon 4/\varepsilon 4$ compared to $\varepsilon 4$ -negative in Japanese population [Farrer 1997]), and they are more 61 prevalent than those with familial AD mutations in the general population [Nicolas 2016]. While 62 APOE genotype testing has not been covered by health insurance [Arias 2021], it may become more 63 common testing with the recent approval of anti-amyloid therapies (such as lecanemab [van Dyck 64 2023] and donanemab [Sims 2023]) and the subsequent need to stratify the risk of developing a 65 specific adverse effect called Amyloid-Related Imaging Abnormalities (ARIA) [Sperling 2011]. This, 66 in turn, may lead to an increase in the number of people unexpectedly found to be $\varepsilon 4$ homozygous at 67 their asymptomatic stage, when there is no treatment available, apart from the requirement for testing 68 in the context of anti-amyloid treatment.

Currently, private insurance companies in some regions and countries – mainly Western
countries – are not allowed to use genetic information in their underwriting process to prevent
genetic discrimination [Muto 2023]. For example, in the United States, it is legally prohibited for
medical insurance under federal law, and for other kinds of insurance under state law in some states.
In Japan, it is self-regulated by insurance industry association based on a voluntary guideline issued
in May 2022 [The Life Insurance Association of Japan 2022]. Current underwriting and payment

It is made available under a CC-BY-ND 4.0 International license .

75 practices for dementia insurance in Japan do not exclude individuals with a genetically high risk of 76 developing AD, regardless of whether they know their objective risk in advance, as long as they are 77 asymptomatic at the time of insurance purchase.

78 Private insurance products targeting the general population and operated by for-profit 79 companies are, like lotteries, basically loss-making in terms of expected income versus expenses 80 from the viewpoint of the insured. The same can be said for dementia insurance, where it is 81 estimated that more than half of the policyholders would be relatively low-risk, APOE ɛ4-negative 82 people. On the other hand, ɛ4-homozygotes are especially susceptible to developing AD, as well as 83 experiencing ARIA during anti-amyloid therapy, and specific opportunities of research and trials for 84 this group are gaining recognition [Fortea 2023]. Given the high risk of developing AD in 85 ϵ 4-homozygotes, we hypothesized that there could possibly be a surplus in terms of expected income 86 versus expenses for those who are ε 4-homozygotes, or that the dementia insurance may be at least 87 more economical for ε 4-homozygotes than for ε 4-negative individuals. If so, can dementia insurance 88 possibly be an option for ε 4-homozygotes to mitigate their future disease burden? 89 This study aims to examine the cost-effectiveness of dementia insurance from the 90 perspective of the insured individuals, using long-term, large observational data to emulate the 91 development of AD and dementia within the longitudinal insurance policyholding history. We apply 92 the actual premium rate settings of dementia insurance products sold in Japan to the data, thereby 93 simulating the balance of income and expenses at the genotype group level, and clarifying the degree 94 of cost-effectiveness of dementia insurance for the ε 4-homozygotes compared to other genotypes 95 under Japanese circumstances. 96

97 2 Methods

98 2.1. Study Design

99 This is a retrospective study using National Alzheimer's Coordinating Center (NACC) data, a

100 publicly-available database that includes observational data of more than 50,000 unique participants

101 collected from Alzheimer's Disease Research Centers in the United States [Beekly 2004]. Our study
102 was approved by a local ethics committee [ID:11754-(1)]. Our study requires a sufficient number of
103 participants with two ε4 alleles with a considerable length of observation period, making the NACC
104 data suitable for our simulation despite it being obtained from North American citizens. We applied
105 the actual premium rate settings of dementia insurance products sold in Japan.

106

107 2.2. Simulation Settings

108 We regarded the NACC longitudinal observation data of participants, from their baseline to the 109 development of dementia or dropout from the study, as the longitudinal policyholding data of insured 110 individuals. The maximum length of follow-up for NACC participants is approximately 18 years. Let 111 us consider a typical dementia insurance product to simulate: cognitively unimpaired middle-aged or 112 elderly individuals within a certain age range (e.g., 50-75 years old) at enrollment, without 113 significant past medical history that may directly influence cognitive function, are eligible to 114 purchase the insurance. The insured pay a fixed monthly premium until death or policy cancellation, 115 and receive a lump-sum benefit when they are diagnosed with dementia for the first time, regardless 116 of the cause. For simplicity, we set the benefit as JPY 1,000,000 (= USD 6,250 when USD 1 =JPY 117 160) for this analysis.

118 We searched the Internet on July 1, 2024, using a Japanese keyword equivalent to 119 "dementia insurance", and identified nine simplified-issue dementia insurance products with details 120 available online (Table S1). All provided a primary benefit of a one-time diagnostic lump-sum 121 payment, with exclusion period of up to 2 years from the purchase date. The conditions for receiving 122 benefits were similar across products, with many requiring diagnosis of non-treatable dementia by a 123 physician, and some additionally requiring certification of nursing care necessity in the LTC 124 insurance system. Common reasons for denial of insurance coverage included concurrent 125 hospitalization, a history of neuropsychiatric diseases including MCI or dementia, applying for or 126 being certified for public LTC insurance benefits, and recent surgery or hospitalization. The age

It is made available under a CC-BY-ND 4.0 International license .

range for whole-life dementia insurance largely overlapped across products, with a typical minimumage of 40 and maximum of 79.

Among these products, we selected two whole-life dementia insurance products, where the premium rate for diagnostic coverage of dementia development was available by sex and detailed age at enrollment, and where the insurance benefit was lump-sum JPY 1,000,000 without additional plans required to include. The names of these products or companies are not publicized in this study, as reviewing specific products in an identifiable manner is not the aim of this study.

For simulation using NACC data, we included participants whose Clinical Dementia Rating global score (CDR-GS) was 0 at baseline, who had visited study site twice or more, who had no specific medical history (i.e., stroke, Parkinson's disease, alcohol abuse, schizophrenia, bipolar disorder, depression within two years, traumatic brain injury, and any other neurological diseases) at baseline, who had no dominantly-inherited AD mutations, and whose *APOE* genotype information was available. The event of interest (i.e., first development of dementia) was defined as a CDR-GS of 1 or more for the first time during observation.

141

142 2.3. Calculation of Income and Expenses

143 By regarding the NACC longitudinal observation as the insurance policyholding data, we calculated 144 the balance of income and expenses for insured individuals by applying the age-dependent monthly 145 premium data. Figure 1A illustrates several patterns of the period during which monthly premiums 146 were assumed to be paid for up to T years ($1 \le T \le 18$). Pattern (a) represents those without the 147 occurrence of an event within the period of T years, resulting in only premium payments without 148 gaining a benefit. Pattern (b) is for those who developed dementia within the period, and such 149 individuals gain a benefit, having paid premiums until the time of dementia diagnosis. Patterns (c) 150 and (e) resemble the patterns (a) and (b), respectively.

However, pattern (d) requires attention: individuals in this pattern dropped out of the NACC
study without observation of an event during the period, so their income is set to zero. Some of these

It is made available under a CC-BY-ND 4.0 International license .

individuals may have developed dementia after their dropout, meaning their potential income could
be underestimated. To address this, we applied two scenarios for balance calculation: scenario (i)
assumes pattern (d) individuals canceled their insurance at dropout, while scenario (ii) assumes a
fraction of pattern (d) individuals actually developed dementia at dropout. The proportion of those
who developed dementia in scenario (ii) is assumed to be the same as those in patterns [b] and [e]
combined.

159 For a given period of *T* years we can obtain the total income from all participants who

160 developed dementia within the period and total payments made by all participants during their

161 policyholding period. This leads to the calculation of loss ratio [Grace 2023], defined as follows:

Loss ratio = (Paid claims + Loss adjustment expenses)/Earned premium

162 The loss ratio indicates whether an insurance product is financially favorable (< 1) or unfavorable (>

163 1) for the insurance company. Conversely, a higher loss ratio (> 1) is favorable for the insured,

164 indicating a higher expected value of benefits. The loss adjustment expense (LAE) is the cost

165 incurred by the insurance companies for claim verification. For simplicity, we assumed the LAE to

166 be at most 10% of the total claims. The simplified loss ratio from the insured's standpoint is defined

167 as:

Loss ratio' = Gained claims/Paid premium

168 We calculated the loss ratio for each APOE- ε 4 subgroup (ε 4-negative, ε 4-heterozygous, and

169 ϵ 4-homozygous). The ratio of the loss ratio between subgroups was further calculated as:

$Ratio_{homo/negative} = Loss ratio_{homo}/Loss ratio_{negative}$

170 These ratios indicate how much more economical dementia insurance is for the ε 4-homozygotes than 171 for the ε 4-heterozygotes or ε 4-negative individuals. The ratios and their 95% confidence intervals 172 (CIs) are obtained by bootstrapping (B = 1,000). Since younger NACC participants at baseline would 173 be less likely to develop dementia over the 18-year period, we examined the cost-effectiveness

It is made available under a CC-BY-ND 4.0 International license .

174 metrics for all eligible NACC cases, as well as for the subgroups stratified by the age at baseline (i.e.,

- 175 50s or younger, 60s, and 70s or older).
- 176

177 **3 Results**

178 3.1. Included Participants

179 Table 1 shows the baseline characteristics of the examined cognitively unimpaired participants (i.e.,

180 CDR-GS of 0) at baseline. The ε4-heterozygotes and homozygotes accounted for approximately 30%

181 and 4%, respectively. An event (i.e., conversion to $CDR-GS \ge 1$ for the first time) during the

182 observation period was seen in 3.41% of these participants, with the median occurrence in the 7th

183 year from their observation. The median follow-up period was 4.5 years, with a slight difference in

follow-up length by *APOE* genotype (p = 0.021, ANOVA test): a Poisson regression model

185 examining the effect of the number of $\varepsilon 4$ alleles on follow-up length revealed that $\varepsilon 4$ -homozygotes

186 and ε4-heterozygotes had 0.900 and 0.968 times shorter maximum follow-up periods compared to

187 ε4-negative individuals.

188 Figure 1B shows the survival curve of participants until their development of dementia

189 (CDR-GS \geq 1). Cox-proportional hazards analysis, including intercept and APOE- ϵ 4 alleles as

190 explanatory variables, revealed a hazard ratio (HR) for conversion to CDR-GS \geq 1 of 1.899 (95%CI:

191 1.469 ~ 2.456) for ε4-heterozygotes and 4.106 (95%CI: 2.674 ~ 6.305) for ε4-homozygotes,

192 compared to ɛ4-negative individuals.

193

194 3.2. Loss Ratio by APOE Genotype

195 Figure 2A shows the loss ratio in each ε 4 subgroup, based on the any baseline age of participants, for

196 different observation periods T ($1 \le T \le 18$). In either insurance product ([a] or [b]), for observation

197 periods \geq 10 years, the loss ratio was highest in the APOE- ϵ 4 homozygotes, followed by

198 heterozygotes and ɛ4-negative individuals. The loss ratio for ɛ4-negative individuals remained

199 consistently low, regardless of the examined range of T. As T increased, the estimated loss ratio

It is made available under a CC-BY-ND 4.0 International license .

200 notably rose for ɛ4-homozygotes, irrespective of the scenario assumed ([i] or [ii]). Meanwhile, the

201 loss ratio did not exceed the economically favorable threshold (loss ratio = 1) even for

202 ε4-homozygotes.

Figure S1 shows the distribution of loss ratio by baseline age subgroup (50s or younger

204 [Figure S1A], 60s [Figure S1B], and 70s or older [Figure S1C]). Since ε4-homozygotes in their 50s

at baseline did not convert to dementia, the loss ratio for individuals in their 50s is zero across all

206 periods (Figure S1A). The loss ratios of individuals in their 60s or older at baseline were similar to

the results for all age combined (Figure 2B, C).

208

209 3.3. Relative Cost-Effectiveness

210 Figure 2B demonstrates the ratio of the loss ratios: ratio(homo/hetero) and ratio(homo/negative). For

211 T = 1, no meaningful ratios were obtained because no ε 4-negative individuals developed dementia

within a 1-year period. Broad 95% CIs spanning 1 were observed for $T = 2 \sim 7$, but the

213 ratio(homo/negative) consistently and significantly exceeded 1, ranging from 3 to 4 at $T \ge 8$. The

214 ratio(homo/hetero) showed a similar distribution, reaching as high as 2 and remaining consistently

and significantly above 1 at $T \ge 12$. The 95% CIs of the ratio(homo/negative) and the

216 ratio(homo/hetero) showed slight overlap.

Figure S2 presents the ratio of the loss ratios distribution by baseline age subgroup (50s or

218 younger [Figure S2A], 60s [Figure S2B], and 70s or older [Figure S2C]). Since ε4-homozygotes in

219 their 50s at baseline did not reveal conversion to dementia, the ratio for individuals in their 50s at

baseline is zero or all periods (Figure S2A). The ratios for individuals in their 70s or older at baseline

221 were similar to the all-age results (Figure S2C), while the ratios for those in their 60s showed limited

- difference between the ratio(homo/negative) and the ratio(hetero/negative) (Figure S2B).
- 223

224 4 Discussion

It is made available under a CC-BY-ND 4.0 International license .

225 In this study, we examined the cost-effectiveness of dementia insurance from the perspective of the 226 insured, using longitudinal NACC data to simulate the development of dementia and the subsequent 227 group-level income and expenses. As a result, we found that the estimated loss ratio for 228 ϵ 4-homozygotes increases as the length of the observation period extends, while the loss ratio for 229 ϵ 4-negative individuals remains low regardless of the duration of the period examined (up to 230 18-year). Furthermore, we identified the loss ratio for ε 4-homozygotes is 2 and 3-4 times better than 231 that for e4-heterozygotes and for ε 4-negative individuals, respectively, especially among those in 232 their 60s-70s at baseline. These results suggest that non-demented ε 4-homozygotes of this age group 233 may find it significantly more economical to purchase dementia insurance than ε 4-negative 234 individuals, provided the insurance policy is held for 10 years or longer. Asymptomatic 235 ε4-homozygotes are known as susceptible to developing AD and experiencing ARIA during 236 anti-amyloid therapy, and specific opportunities of research and trials for them are getting 237 recognized [Fortea 2023]. Dementia insurance could potentially serve as a form of support to 238 mitigate their future disease burden. Our results will provide an important basis for further 239 investigating the advantages and shortcomings of dementia insurance for asymptomatic but high-risk 240 people, not limited to APOE-E4 homozygotes. 241 A major characteristic of this study is applying actual premium rate settings to longitudinal

observational data, treating it as the longitudinal insurance history data of the insured. The dementia
insurance itself is designed based on the probability of dementia development in the target
population; however, there is limited statistical data on the long-term probability of dementia
conversion in ε4-homozygotes, as required in our study. This is an advantage of our approach, which
overcomes the data shortage.

Meanwhile, simulations using observational data require careful interpretation. NACC participants may be either less or more motivated to continue participating in the study than insured individuals are to maintain an insurance policy. If so, mid-study dropouts from the NACC data may not always be equivalent in frequency to the cancellation of an insurance policy during the period

It is made available under a CC-BY-ND 4.0 International license .

251	(i.e., scenario [i]). Additionally, the participants' age significantly influenced the level of
252	cost-effectiveness (Figure S1, S2), due to their difference in the prevalence of dementia development.
253	We were unable to conduct meaningful discussions on the results from participants who were in their
254	50s or younger (Figure S1A, S2A). Furthermore, although the prevalence of APOE-E4 genotypes in
255	the examined NACC data - APOE-E4-heterozygotes 30% and homozygotes 4% - was not far from
256	real-world estimates, as previously reported [Husain 2021], there is no guarantee that the proportion
257	of ɛ4-heterozygotes and homozygotes among actual dementia insurance policyholders would be
258	consistent with the prevalence observed in this study. In addition, since the premium rate settings
259	applied were those of dementia insurance sold in Japan, the calculated loss ratio might differ from
260	our results if we had used the premium rate of insurance policies sold in the United States.
261	For these reasons, the value of the loss ratio itself, as estimated in this study (Figure 2A) for
262	each ɛ4 genotype, may not be completely reliable. This is also suspect from the aspect of the degree
263	of the loss ratio in ɛ4-negative individuals (Figure 2A), who should be the majority of the insured: it
264	is lower than 0.25 and appears too favorable for the insurance companies, so the loss ratio estimated
265	in our simulation may actually be underestimated to a considerable degree. This is the major
266	limitation of our study. Although another scenario, assuming that some of the dropout participants
267	had actually developed dementia (i.e., scenario [ii]), attempted to address these shortcomings by
268	demonstrating a larger loss ratio than in the scenario [i], it is necessary to identify the precise method
269	to correct for mid-way dropout cases.
270	In turn, the relative relationship of the loss ratio between different genotypes, i.e., ratio in
271	the loss ratios (Figure 2B), might be more robust against the shortcomings of directly referring to the
272	loss ratio value. Although this is another measure of cost-effectiveness, it does not directly tell us

273 how economical dementia insurance is, but rather indirectly shows how much more economical

- 274 dementia insurance is for ε 4-homozygotes are than for other ε 4 genotypes. This is also easy to
- 275 understand intuitively, as the ratio in the loss ratios largely corresponds to the risk of developing
- 276 dementia: the loss ratio for ε4-homozygotes was approximately 3 ~ 4 and 2 times consistently higher

It is made available under a CC-BY-ND 4.0 International license .

than for ε 4-negative and ε 4-heterozygous individuals, respectively, and the HR for conversion to CDR-GS \ge 1 was approximately 2 for ε 4-heterozygotes and approximately 4 for ε 4-homozygotes. Higher cost-effectiveness here means that ε 4-homozygotes will have 3 to 4 times more expected benefits to gain compared to ε 4-negative individuals, as well as similar expected benefits with 3 to 4 times lower premium payments than ε 4-negative individuals. Based on these evaluations, some ε 4-homozygotes in their 60s-70s may find dementia insurance valuable to purchase.

283 Evaluating dementia insurance as valuable for ε 4-homozygotes does not necessarily mean 284 recommending APOE testing when considering purchasing dementia insurance, or does it encourage 285 actively pursuing APOE testing for asymptomatic individuals as a way to secure insurance with high 286 odds of payoff. Dementia insurance is usually offered only to those without cognitive decline, and 287 APOE testing is only considered for individuals who may receive anti-amyloid treatment as part of 288 the risk assessment for developing ARIA [Cummings 2023], with treatment currently limited to MCI 289 or mild AD. This means that people considering purchasing dementia insurance will generally not 290 have access to APOE testing in current usual clinical practice. In addition, the prevalence of 291 E4-homozygote remaining cognitively unimpaired in their 60s-70s is relatively not high: for example, 292 it has been reported that approximately 60% and 40% of cognitively unimpaired ɛ4-homozygotes in 293 their 60s and 70s, respectively, remain stable over the next 8 years [Bonham 2016]. In these respects, 294 there may be limited situations where our finding will be clearly applicable.

295 Meanwhile, it is technically possible for ε 4-homozygotes to know their ε 4 genotype, such as 296 through *APOE* testing services offered in medical practices not covered by health insurance [Sato 297 2024(a)], via direct-to-consumer services [Pavarini 2021], or by participating in prevention trials or 298 clinical studies related to AD. Indeed, our previous online survey [Sato 2024(b)] revealed that 299 approximately 45% of questionnaire respondents expressed a willingness to undergo APOE testing, 300 even without the immediate need for testing prior to anti-amyloid treatment [Sato 2024(c)]. If the 301 potential cost-effectiveness of dementia insurance for ε 4-homozygotes becomes widely recognized, 302 it may lead to adverse selection, with ε 4-homozygotes being more likely to concentrate in dementia

It is made available under a CC-BY-ND 4.0 International license .

303	insurance policies far more than the general population, resulting in a significant increase in paid
304	benefits for insurance companies, and eventually necessitating higher premiums or the
305	discontinuation of dementia insurance products in the long term. It may also lead to the misuse of
306	APOE testing. Therefore, we do not recommend actively seeking APOE testing when considering
307	purchasing dementia insurance. However, it may be unavoidable to consider dementia insurance for
308	exceptional cases, such as those who already know their ϵ 4 status before deciding to purchase
309	insurance. A similarly complex discussion on risk stratification by APOE testing prior to purchasing
310	insurance may also apply to blood-based biomarker (BBM) testing results, which now provides
311	highly accurate predictions of pre-symptomatic pathological changes in AD [Niimi 2024], although
312	it is not a genetic test.
313	In conclusion, our study demonstrated that dementia insurance may be more cost-effective
314	for APOE-E4 homozygotes compared to other genotypes. Although the dementia insurance could
315	serve as a potential supportive option to alleviate the future potential disease burden for some
316	ε4-homozygotes, we would need further investigation on the advantages and limitations of dementia
317	insurance for asymptomatic individuals with pathogenic or high-risk genes, including but not limited
318	to APOE-ε4 homozygotes.
319	
320	5 Conflict of Interest
321	The authors declare that the research was conducted in the absence of any commercial or financial
322	relationships that could be construed as a potential conflict of interest.
323	
324	6 Author Contributions
325	KS: Conceptualization, Study Design, Data Acquisition, Data Curation, Analysis, Writing draft. SN:
326	Data Acquisition, Review & Editing. YN: Review & Editing. TI: Supervision. All authors read and
327	approved the final manuscript.
0.00	

It is made available under a CC-BY-ND 4.0 International license .

329 7 Funding

330	Thi	s study was supported by AMED Grant Numbers JP23dk0207048 (TI) and JP24dk0207054 (YN),
331	and	JSPS KAKENHI Grant Number JP24K10653 (KS). The sponsors had no role in the design and
332	con	duct of the study; collection, analysis, and interpretation of data; preparation of the manuscript;
333	or r	review or approval of the manuscript.
334		
335	Re	ferences
336	1.	Yamazaki H. Dementia and Life Insurance ~Development and Background of Dementia
337		Insurance Products~. Japanese Journal of Insurance Medicine (2020). 118;2:162-171. [Article in
338		Japanese]
339	2.	Park KW, Kim JY. New Proposal of Private Insurance Program for Dementia Patients: Design of
340		Sustainable Private Insurance Program in Korea. Dement Neurocogn Disord. 2017
341		Mar;16(1):1-6. doi: 10.12779/dnd.2017.16.1.1.
342	3.	Reinsurance Group of America. South Korea Provides a Road Map for Dementia Insurance.
343		(https://www.rgare.com/knowledge-center/article/south-korea-provides-a-road-map-for-dementi
344		a-insurance) Accessed on July 1, 2024.
345	4.	Šestáková, A., & Plichtová, J. (2020). More than a medical condition: Qualitative analysis of
346		media representations of dementia and Alzheimer's disease. Human Affairs, 30(3), 382-398.
347	5.	Goncharova, N. L. (2020). Development of financial service methods for people with dementia
348		during digitalization: a partnership between citizens and the Russian state. International Journal
349		of Technology, 11(8).
350	6.	Eisai Global. Lifenet and Eisai Co-Develop Dementia Insurance "be".
351		(https://www.eisai.com/news/2024/news202416.html) Accessed on September 30, 2024.
352	7.	Muramatsu N, Akiyama H. Japan: super-aging society preparing for the future. Gerontologist.
353		2011 Aug;51(4):425-32.

354 8. Japan Population Census. Ministry of Internal Affairs and

- 355 Communications. (https://www.e-stat.go.jp/stat-search/files?toukei=00200524) Accessed on July
- 356 1, 2024. [Article in Japanese]
- 357 9. Japan Institute of Life Insurance. National Survey on Life Insurance.
- 358 (https://www.jili.or.jp/research/report/zenkokujittai.html): Accessed on July 1, 2024.
- 359 10. Tamiya N, Noguchi H, Nishi A, Reich MR, Ikegami N, Hashimoto H, Shibuya K, Kawachi I,
- 360 Campbell JC. Population ageing and wellbeing: lessons from Japan's long-term care insurance
- **361** policy. Lancet. 2011 Sep 24;378(9797):1183-92.
- 362 11. Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P,
- 363 Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ. Tracking
- 364 pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic
- 365 biomarkers. Lancet Neurol. 2013 Feb;12(2):207-16.
- 366 12. Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk,
 367 mechanisms and therapy. Nat Rev Neurol. 2013 Feb;9(2):106-18. doi:
- 368 10.1038/nrneurol.2012.263. Epub 2013 Jan 8. Erratum in: Nat Rev Neurol. 2013.
- 369 13. Nicolas G, Charbonnier C, Campion D. From Common to Rare Variants: The Genetic
- 370 Component of Alzheimer Disease. Hum Hered. 2016;81(3):129-141.
- 14. Husain MA, Laurent B, Plourde M. APOE and Alzheimer's Disease: From Lipid Transport to
- 372 Physiopathology and Therapeutics. Front Neurosci. 2021 Feb 17;15:630502.
- 373 15. Fortea J, Pegueroles J, Alcolea D, Belbin O, Dols-Icardo O, Vaqué-Alcázar L, Videla L, Gispert
- 374 JD, Suárez-Calvet M, Johnson SC, Sperling R, Bejanin A, Lleó A, Montal V. APOE4
- homozygozity represents a distinct genetic form of Alzheimer's disease. Nat Med. 2024
- **376** May;30(5):1284-1291.
- 377 16. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH,
- 378 Pericak-Vance MA, Risch N, van Duijn CM. Effects of age, sex, and ethnicity on the association
- between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and
- 380 Alzheimer Disease Meta Analysis Consortium. JAMA. 1997 Oct 22-29;278(16):1349-56.

- 381 17. Arias JJ, Tyler AM, Douglas MP, Phillips KA. Private payer coverage policies for ApoE-e4
- **382** genetic testing. Genet Med. 2021 Apr;23(4):614-620.
- 383 18. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D,
- Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S,
- 385 Irizarry M, Kramer LD, Iwatsubo T. Lecanemab in Early Alzheimer's Disease. N Engl J Med.
- **386** 2023 Jan 5;388(1):9-21.
- 387 19. Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang
- 388 H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C,
- Brooks DA, Mintun M, Skovronsky DM; TRAILBLAZER-ALZ 2 Investigators. Donanemab in
- 390 Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
- **391** JAMA. 2023 Aug 8;330(6):512-527.
- 392 20. Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo
- 393 MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH,
- 394 Schindler RJ. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials:
- recommendations from the Alzheimer's Association Research Roundtable Workgroup.
- **396** Alzheimers Dement. 2011 Jul;7(4):367-85.
- 397 21. Muto K, Nagai A, Ri I, Takashima K, Yoshida S. Is legislation to prevent genetic discrimination
- 398 necessary in Japan? An overview of the current policies and public attitudes. J Hum Genet. 2023
- 399 Sep;68(9):579-585. doi: 10.1038/s10038-023-01163-z. Epub 2023 Jun 8. Erratum in: J Hum
- 400 Genet. 2023 Sep;68(9):587.
- 401 22. The Life Insurance Association of Japan. "Current Handling of Genetic Information in
- 402 Underwriting and Payment Practices. (2022)
- 403 (https://www.seiho.or.jp/info/news/2022/20220527.html): Accessed on July 1, 2024.
- 404 23. Beekly DL, Ramos EM, van Belle G, Deitrich W, Clark AD, Jacka ME, Kukull WA;
- 405 NIA-Alzheimer's Disease Centers. The National Alzheimer's Coordinating Center (NACC)
- 406 Database: an Alzheimer disease database. Alzheimer Dis Assoc Disord. 2004

- 407 Oct-Dec;18(4):270-7. PMID: 15592144.
- 408 24. Grace, M. F. (2023). Loss ratio dynamics. Risk Management and Insurance Review, 26(3),
- 409 343-366.
- 410 25. Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, Hendrix S, Selkoe D,
- 411 Weiner M, Petersen RC, Salloway S. Lecanemab: Appropriate Use Recommendations. J Prev
- 412 Alzheimers Dis. 2023;10(3):362-377.
- 413 26. Bonham LW, Geier EG, Fan CC, Leong JK, Besser L, Kukull WA, Kornak J, Andreassen OA,
- 414 Schellenberg GD, Rosen HJ, Dillon WP, Hess CP, Miller BL, Dale AM, Desikan RS, Yokoyama
- 415 JS. Age-dependent effects of APOE $\varepsilon 4$ in preclinical Alzheimer's disease. Ann Clin Transl
- 416 Neurol. 2016 Aug 26;3(9):668-77.
- 417 27. Sato K (a), Niimi Y, Ihara R, Iwata A, Ikeuchi T, Iwatsubo T. Advertisement by medical facilities
- 418 as an opportunity route of APOE genetic testing in Japan: a website analysis. J Community
- 419 Genet. 2024 Apr;15(2):195-204.
- 420 28. Pavarini G, Hamdi L, Lorimer J, Singh I. Young people's moral attitudes and motivations
- 421 towards direct-to-consumer genetic testing for inherited risk of Alzheimer disease. Eur J Med 422
- Genet. 2021 Jun;64(6):104180.
- 423 29. Sato K (b), Niimi Y, Ihara R, Suzuki K, Iwata A, Iwatsubo T. Usability of a Web-Based Registry
- 424 for Preclinical Alzheimer's Disease: Implications from a Cross-Sectional Online Survey. J Prev 425 Alzheimers Dis. 2024;11(3):661-671.
- 426 30. Sato K (c), Niimi Y, Ihara R, Iwata A, Suzuki K, Nemoto K, Arai T, Higashi S, Igarashi A,
- 427 Kasuga K, Awata S, Iwatsubo T. Public perceptions related to healthcare preparedness to
- 428 anti-amyloid therapies for Alzheimer's Disease in Japan. Alzheimers Res Ther. 2024 Oct 429 3;16(1):205.
- 430 31. Niimi Y, Janelidze S, Sato K, Tomita N, Tsukamoto T, Kato T, Yoshiyama K, Kowa H, Iwata A,
- 431 Ihara R, Suzuki K, Kasuga K, Ikeuchi T, Ishii K, Ito K, Nakamura A, Senda M, Day TA,
- 432 Burnham SC, Iaccarino L, Pontecorvo MJ, Hansson O, Iwatsubo T. Combining plasma Aβ and

- 433 p-tau217 improves detection of brain amyloid in non-demented elderly. Alzheimers Res Ther.
- **434** 2024 May 23;16(1):115.
- 435
- 436

It is made available under a CC-BY-ND 4.0 International license .

437 Tables

	Total N	9,306
Fol	llow-up period (years)	Median 4.5 (IQR: 1.7 ~ 8.5)
	Sex (female)	6,074 (65.3%)
	Age at baseline	Median 69 (IQR: 64 ~ 73)
	50s or less	1,280 (13.7%)
Age	60s	3,760 (40.4%)
	70s	4,266 (45.8%)
	Negative	6,206 (66.7%)
ΑΡΟΕ-ε4	Heterozygous	2,759 (29.6%)
	Homozygous	341 (3.7%)
Daga	White (vs others)	7,116 (76.5%)
Race	Black (vs others)	1,676 (18.0%)
	Education years	Median 16 (IQR: 14 ~ 18)
CD	R-GS at baseline $(= 0)$	9,306 (100%)
С	DR-SOB at baseline	Median 0 (IQR: 0 ~ 0)
	MMSE at baseline	Median 29 (IQR: 29 ~ 30)
Became ($CDR-GS \ge 1$ within 18 years	391 (4.2%)
Timing whe	en CDR-GS became ≥ 1 (years)	Median 7.7 (IQR: 5.0 ~ 11.3)
Amyloic	l positive (in PET or CSF)*	89/371 (24.0%)

438 Table 1. Basic characteristics of NACC participants whose age at baseline is 40-79

439 (*) Amyloid data has been obtained only in a fraction of participants.

440

441	Abbreviations:	NACC.	National	Alzheimer's	Coordinating	Center: IOR	, interquartile range;

442 CDR-GS, Clinical Dementia Rating Global Score; CDR-SOB, Clinical Dementia Rating Sum of

443 Boxes; MMSE, Mini-Mental State Examination; PET, positron emission tomography; CSF,

444 cerebrospinal fluid.

It is made available under a CC-BY-ND 4.0 International license .

446 Figure Legends

447	Figure 1. Several patterns	in simulating policyholding based	on NACC longitudinal observation, and
-----	----------------------------	-----------------------------------	---------------------------------------

448 survival curve by *APOE* genotype

449

450	In (A), several patterns	of the period during	which the monthly premium	is assumed to be paid for up
		1 0	21	1 1

451 to *T* years ($1 \le T \le 18$) are illustrated. Patterns (a), (c), and (d) represent cases without the

- 452 occurrence of an event (i.e., development of dementia) within the *T*-year period, while patterns (b)
- 453 and (e) represent cases where the development of dementia is observed during the period. Diamond
- 454 shapes in the schema denote the occurrence of the event during the longitudinal observation, and
- 455 double arrows indicate the period in which the insured are to pay monthly premium.
- 456 The survival curve of the included participants until their development of dementia
- 457 (CDR-GS \geq 1) is shown in (B). Cox-proportional hazards analysis revealed that the hazard ratio
- 458 (HR) for conversion to CDR-GS \geq 1 was 1.899 for ϵ 4-heterozygotes and 4.106 for ϵ 4-homozygotes,
- 459 compared to ε 4-negative individuals.
- 460
- 461 Abbreviations: NACC, National Alzheimer's Coordinating Center; CDR-GS, Clinical Dementia
 462 Rating global score.


463


It is made available under a CC-BY-ND 4.0 International license .


465 Figure 2. Loss ratio by ε4 subgroup, and the ratio in the loss ratios

466


467	In either insurance product ([a] or [b]), for observation periods of ≥ 10 years, the loss ratio (A) was
468	highest in the APOE-E4 homozygotes, followed by heterozygotes, and E4-negative individuals. The
469	loss ratio for ε 4-negative individuals remained low regardless of the examined range of <i>T</i> . As <i>T</i>
470	increased, the estimated loss ratio rose, particularly for ɛ4-homozygotes, regardless of whether
471	scenario ([i] or [ii]) was assumed. Meanwhile, the loss ratio did not surpass the threshold of
472	economically favorable level (loss ratio = 1), even for ε 4-homozygotes.
473	The ratio of the loss ratios are shown in (B): ratio(homo/hetero) and ratio(homo/negative).
474	Especially broad 95% CIs spanning 1 are observed for $T = 2 \sim 7$, and the ratio(homo/negative)
475	reaches as high as 3 ~ 4, consistently and significantly higher than 1 at $T \ge 8$. The ratio(homo/hetero)
476	also displayed a similar pattern, reaching as high as 2, and was consistently and significantly higher
477	than 1 at T \geq 12. The 95%CIs of the ratio(homo/negative) and the ratio(homo/hetero) show slight
478	overlap with each other.
479	








- --- ε4-homo / ε4-negative
- -- ε4-homo / ε4-hetero





ε4-homo / ε4-negative
 ε4-homo / ε4-hetero